2023
Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry
Maurizi N, Day S, Ashley E, Michels M, Pereira A, Helms A, Saberi S, Jacoby D, Ware J, Colan S, Semsarian C, Ingles J, Ho C, Olivotto I. Long term outcome after septal reduction therapies in patients with hypertrophic cardiomyopathy: insights from the SHaRe registry. European Heart Journal 2023, 44: ehad655.1852. DOI: 10.1093/eurheartj/ehad655.1852.Peer-Reviewed Original ResearchLong-term outcomesPeri-procedural mortalityAlcohol septal ablationTerm outcomesHF outcomesComposite outcomeLV maximal wall thicknessDilated left atriumSeptal reduction therapyPredictor of prognosisMaximal wall thicknessPost-operative resultsProportional hazards modelMost available studiesLA diameterSeptal ablationVA outcomesHeart failureOverall mortalityLV EFVentricular arrhythmiasHF eventsHCM patientsSarcomeric mutationsSpecialty centers
2020
Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights from the SHaRe Registry
Marstrand P, Han L, Day SM, Olivotto I, Ashley EA, Michels M, Pereira AC, Wittekind SG, Helms A, Saberi S, Jacoby D, Ware JS, Colan SD, Semsarian C, Ingles J, Lakdawala NK, Ho CY. Hypertrophic Cardiomyopathy with Left Ventricular Systolic Dysfunction: Insights from the SHaRe Registry. Circulation 2020, 141: 1371-1383. PMID: 32228044, PMCID: PMC7182243, DOI: 10.1161/circulationaha.119.044366.Peer-Reviewed Original ResearchConceptsLeft ventricular systolic dysfunctionVentricular ejection fractionComposite outcomeHypertrophic cardiomyopathyNatural historyEjection fractionLeft ventricular cavity sizeVentricular systolic dysfunctionPredictor of prognosisVentricular cavity sizeProportional hazards modelSignificant predictorsSystolic dysfunctionMedian timeAtrial fibrillationSpecialty centersSarcomeric variantsHazards modelIncident developmentPatientsEnd stageRelative rarityPrognosisOutcomesPredictors